» Products and Services » Drug-to-target and Off-Target discovery

Which target can explain the observed biological and clinical evidences?

A deep knowledge about the molecular targets of a compound is essential to capitalize on its full potential and avoid pitfalls in clinical studies. Anaxomics helps you understand the whole target profile of the drugs in your pipeline with a combination of structure-based and systems biology approaches.

With the emergence of a molecular target-based paradigm in the pharmaceutical industry, acquiring knowledge of a compound's target profile has become an essential first step in drug discovery. A deep comprehension of drugs' molecular site of action allows you to maximize the value of your discoveries by evaluating potential new indications, anticipating adverse events and avoiding pitfalls in clinical trials.

On this account, Anaxomics has developed an integrative approach for new target discovery that combines the latest advances in systems biology with structure-based techniques. Our mixed strategy allows pharmaceutical and biotechnological companies to fully understand the target profile of the compounds under development or already in the market.

In short, we employ various chemical modelling approaches to identify potential targets and off-targets of a compound. Later, we filter and rank the results from these techniques with our proprietary Therapeutic Performance Mapping System (TPMS), so that only those that may explain clinical and preclinical observations remain.

drug-to-target

You can read more about this strategy in our technology section